Company Update: Celgene Corporation (NASDAQ:CELG) – Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016

[Business Wire] – Celgene Corporation today announced more than 65 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 52ndAmerican Society of Clinical Oncology meeting in Chicago, Ill. Read more on this. Celgene Corporation (CELG) , valued at $78.30B, opened this morning at $100.36. During today’s session, CELG traded between $100.06 to $102.04 with a trailing 52-week range being $92.98 to $140.72. CELG shares are currently priced at 17.63x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 1.83x forward p/e ratio. According to a consensus of 23 analysts, the earnings estimate of $1.39 per share would be $0.16 better than the year-ago quarter and a $0.03 sequential decrease. Investors should also note that the full-year EPS estimate of $5.68 is a $0.97 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $2.70 Billion. If realized, that would be a 18.42% increase over the year-ago quarter. In terms of ratings, Citigroup Initiated CELG at Buy (Feb 25, 2016). Previously, Credit Suisse Initiated CELG at to Outperform. The average price target for CELG shares by the analysts covering the stock is $136.82, which is 36.33% above where the stock opened this morning. See more in (NASDAQ:CELG) Similar Articles: Market Update (NASDAQ:CELG): Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates Stock Update (NASDAQ:CELG): Celgene Corporation Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors Stock Update (NASDAQ:CELG): Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results